https://www.selleckchem.com/products/ms-275.html
Targeting the Wnt signaling pathway via modulating CAF may be a potential therapeutic approach.Background Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze the resistance mechanisms acquired after treatment with Osimertinib. Methods Clinical outcomes and molecular results from re-biopsies at the time of
Like
Comment
Share
